Eric Vivier: Three prominent NK cell subsets in human
Katy Rezvani shared a post by Eric Vivier, President at Paris Saclay Cancer Cluster, on X, adding:
“Many congratulations to Eric Vivier and collaborating labs in Europe and the US on this outstanding research! Excited to see these groundbreaking data published.”
Quoting the post by Eric Vivier: .
“Thrilled to announce the publication of our latest research in Nature Immunology. Joining forces with 20 laboratories in Europe and USA, we identified the three prominent NK cell subsets in human: NK1, NK2, and NK3.”
Source: Katy Rezvani/X and Eric Vivier/X
Katy Rezvani, holds roles including Professor of Medicine, Director of Translational Research, and Chief of the Section of Cellular Therapy at MD Anderson Cancer Center. Previously, she directed stem cell transplant programs and research laboratories at Hammersmith Hospital, London. Dr. Rezvani’s research focuses on enhancing natural killer (NK) cell function against leukemia, utilizing genetic engineering techniques. Her work has led to funded Phase I/II trials in leukemia and lymphoma immunotherapy.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023